Home

Catherine M. Szyman

CIK 1438538 · Chief Executive Officer · last filed 2026-06-12

Catherine M. Szyman is a Chief Executive Officer who has filed 120 SEC Form 4 insider transactions across 5 companies since 2008. Across all open-market trades the lifetime net is −$46.6M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $10.8M across reported positions. 13 SEC filings were submitted jointly with MEDTRONIC INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$10.75M

Companies

5

Total Filings

120

Lifetime Open-Market Net

-$46.57M

Filer Profile

Reported Address
C/O MASIMO CORPORATION
52 DISCOVERY
IRVINE, CA 92618
Formerly Known As
Szyman Catherine M (2008–2014)
Related Filers
MEDTRONIC INC — 13 joint filings, latest 2014-04-21
MASIMO CORP — 7 joint filings, latest 2026-06-12
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
MASIMO CORP (MASI) Delisted CEO 8,674 $179.95 $1.56M $0 5 2026-03-16
Inari Medical, Inc. (NARI) Delisted Director 0 $79.97 $0 $533.7K 8 2025-02-19
EW CVP, Critical Care 81,287 $89.90 $7.31M -$42.15M 88 2024-09-03
OM Director 1,640 $3.59 $5.9K $0 4 2023-05-31
MDT SrVP & Pres Diabetes 36,521 $94.17 $3.44M -$4.95M 10 2014-03-21

Recent Filings

120 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-12 — Disp (D) −7,605 -$1.37M
2026-03-16 MASIMO CORP (MASI) Delisted Mixed +1,032 -$187.6K EDGAR
2026-03-10 MASIMO CORP (MASI) Delisted Grant (A) — $0 EDGAR
2026-02-13 MASIMO CORP (MASI) Delisted Mixed +6,573 $1.48M EDGAR
2025-03-13 MASIMO CORP (MASI) Delisted Grant (A) — $0 EDGAR
2025-02-19 Inari Medical, Inc. (NARI) Delisted Mixed −22,429 $0 EDGAR
2025-02-14 MASIMO CORP (MASI) Delisted Grant (A) — $0 EDGAR
2024-09-03 EW Mixed +5,380 -$386.9K EDGAR
2024-07-08 EW Tax (F) −258 -$23.8K EDGAR
2024-05-31 Inari Medical, Inc. (NARI) Delisted Grant (A) +4,126 $175.0K EDGAR
Showing 1–10 of 120
Page 1 of 12
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.